Filtered By:
Specialty: Universities & Medical Training
Condition: Thrombosis
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 257 results found since Jan 2013.
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc scores
CONCLUSIONS: LAD enlargement, HCM, and an elevated CRP level are independent risk factors for atrial thrombosis in NVAF patients with low CHA2DS2-VASc scores.Active anticoagulation therapy should be administered for these patients once these risk factors are detected to prevent the occurrence of stroke.PMID:34549717 | DOI:10.12122/j.issn.1673-4254.2021.08.17
Source: Journal of Southern Medical University - September 22, 2021 Category: Universities & Medical Training Authors: M Zhou J Chen H Wang S Xi T Gan L Zhao Source Type: research
